CADTH | Evidence Driven
CADTH | Evidence Driven

insulin icodec

Details

Generic Name:
insulin icodec
Project Status:
Pending
Therapeutic Area:
Diabetes mellitus, type 2
Manufacturer:
Novo Nordisk Canada Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0790-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
the once-weekly treatment of adults with type 2 diabetes mellitus to improve glycemic control.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
​The once-weekly treatment of adults with diabetes mellitus to improve glycemic control.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Last Updated : September 6, 2023